CORE--PHARMACOANALYTIC CORE LABORATORY

核心--药物分析核心实验室

• 批准号: 6218789
• 负责人: ALFRED E STAUBUS
• 金额: $ 6.51万
• 依托单位: OHIO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-07-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6218789
• 关键词: biomedical facility; liquid chromatography; mass spectrometry; neoplasm /cancer pharmacology

The major goal of the Pharmacoanalytic Laboratory is to provide analytical tools and methodologies to guide clinical investigations on new and existing drugs, including high priority clinical trials, as well as pilot protocols for feasibility studies. The scope of the Service includes characterization of clearance, measurement of biologic half-lives, assessment of apparent volumes of distribution, and metabolic profiles in terms of population-base and/or on an individual patient basis. The number of users is relatively small and it is difficult to determine the use by peer-reviewed projects. The facility has recently added mass spectrometry capability.

药物分析实验室的主要目标是提供分析 指导新的和新的临床研究的工具和方法 现有药物，包括高度优先的临床试验以及试点 可行性研究协议。 服务范围包括 清除率表征、生物半衰期测量、 评估表观分布体积和代谢特征 以人群为基础和/或以个体患者为基础。 这 用户数量相对较少，难以确定 由同行评审项目使用。 该设施最近增加了质量 光谱测定能力。